In addition, studies in head and neck and non-small cell lung cancer cells have shown reactivation of Stat3 signaling in the presence of dasatinib, indicating that these cancers have become resistant to dasatinib by finding a way to sustain Stat3 signaling [37, 56]. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.